GlassScriptPhysician profile
Tatyana Simutkin
NPI 1356875884
$1,324.21
in general payments reported to CMS, 2019-2025
14 companies · $529 in 2025
The $529 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $726 · 2024: $69.33 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.21 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $315.24 | 2023-2024 | Mavenclad |
| Biogen, INC. | $250.00 | 2023-2025 | Tysabri |
| Leo Pharma INC. | $220.21 | 2025 | Adbry |
| Genentech, INC. | $215.40 | 2023-2025 | Ocrevus |
| Abbvie INC. | $75.61 | 2023 | |
| Alexion Pharmaceuticals, INC. | $60.47 | 2023 | |
| Neurocrine Biosciences, INC. | $32.89 | 2023 | Ingrezza, Ongentys |
| Ani Pharmaceuticals, INC. | $26.60 | 2023 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $24.44 | 2023 | Austedo Xr |
| Acadia Pharmaceuticals INC | $23.59 | 2023 | Nuplazid |
| Csl Behring | $22.62 | 2023 | Hizentra |
| Mdd US Operations, LLC | $22.17 | 2023 | Gocovri |
| Sk Life Science, INC. | $19.37 | 2023 | |
| Lilly USA, LLC | $15.60 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatyana Simutkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.